Maze Therapeutics, Inc. — Form 8-K
Filed October 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
On October 15, 2026, Maze Therapeutics exchanged 2,776,007 common shares held by four Frazier Life Sciences funds (X, XI, XII, and Public Fund) for an equivalent number of pre-funded warrants to purchase common stock. The exchange was structured under Section 3(a)(9) of the Securities Act, with no cash consideration or intermediary fees. The warrant shares will be reserved and exercisable under the warrant terms; Frazier funds retain the right to conduct additional exchanges subject to company consent.
Why this rating
Exchange reduces share count by 0.6% of company (2.78M shares vs ~$444M market cap ≈ ~90M shares outstanding). Dilutive to existing shareholders when warrants exercised, but no immediate cash impact or control shift. Routine capital structure adjustment.
See more from October 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.